skip to Main Content

Positive Results Seen in Trial Investigating Nadunolimab Plus Chemotherapy for Advanced Pancreatic Cance

Newsfeed image, light gray text on dark gray background
Positive efficacy results were recently announced regarding nadunolimab (CAN04) plus gemcitabine/nab-paclitaxel to treat patients with advanced pancreatic ductal adenocarinoma (PDAC), according to an announcement from Cantargia AB, the company responsible for the research.

The ongoing, open-label, phase 1/2a CANFOUR trial (NCT03267316) enrolled 36 patients with advanced PDAC, reporting the early efficacy data for the combination treatment in the first-line setting, which compares favorably to the existing historical control data. Read more . . . 

Back To Top